Molecular Ebit Per Revenue from 2010 to 2024

MTEM Stock  USD 0.34  0.04  10.53%   
Molecular Templates Ebit Per Revenue yearly trend continues to be very stable with very little volatility. Ebit Per Revenue is likely to drop to -0.19. During the period from 2010 to 2024, Molecular Templates Ebit Per Revenue quarterly data regression pattern had sample variance of  15,394 and median of (3.61). View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.18)
Current Value
(0.19)
Quarterly Volatility
124.07360095
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Molecular Templates financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Templates' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7 M, Interest Expense of 2.8 M or Other Operating Expenses of 49.9 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0067 or PTB Ratio of 4.19. Molecular financial statements analysis is a perfect complement when working with Molecular Templates Valuation or Volatility modules.
  
Check out the analysis of Molecular Templates Correlation against competitors.
To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.

Latest Molecular Templates' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Molecular Templates over the last few years. It is Molecular Templates' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Templates' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Molecular Ebit Per Revenue Regression Statistics

Arithmetic Mean(40.05)
Geometric Mean3.82
Coefficient Of Variation(309.78)
Mean Deviation62.91
Median(3.61)
Standard Deviation124.07
Sample Variance15,394
Range485
R-Value0.43
Mean Square Error13,479
R-Squared0.19
Significance0.11
Slope12.00
Total Sum of Squares215,520

Molecular Ebit Per Revenue History

2024 -0.19
2023 -0.18
2022 -4.5
2021 -2.07
2020 -6.45
2019 -3.61
2018 -4.26

About Molecular Templates Financial Statements

Molecular Templates investors utilize fundamental indicators, such as Ebit Per Revenue, to predict how Molecular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.18)(0.19)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Molecular Templates is a strong investment it is important to analyze Molecular Templates' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Molecular Templates' future performance. For an informed investment choice regarding Molecular Stock, refer to the following important reports:
Check out the analysis of Molecular Templates Correlation against competitors.
To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.97)
Earnings Share
(3.05)
Revenue Per Share
4.544
Quarterly Revenue Growth
(0.92)
Return On Assets
(0.38)
The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.